APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Targeting Biological Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IL-17 Targeting Biological Drugs Market Outlook and Growth Opportunities 2026

Report ID 174001620429 December 2025195 pages

Choose your research edition.

Industry ResearchIL-17 Targeting Biological Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Targeting Biological Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal IL-17 Targeting Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Targeting Biological Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Targeting Biological Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global IL-17 Targeting Biological Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IL-17 Targeting Biological Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IL-17 Targeting Biological Drugs market include AstraZeneca, DICE Therapeutics, Eli Lilly and Co., Novartis, UCB, Jiangsu Hengrui Medicine, Akesobio and Chongqing Genrix Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-17 Targeting Biological Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-17 Targeting Biological Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-17 Targeting Biological Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-17 Targeting Biological Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-17 Targeting Biological Drugs Segment by Company

AstraZeneca

DICE Therapeutics

Eli Lilly and Co.

Novartis

UCB

Jiangsu Hengrui Medicine

Akesobio

Chongqing Genrix Biopharmaceutical

IL-17 Targeting Biological Drugs Segment by Type

Oral

Injection

IL-17 Targeting Biological Drugs Segment by Application

Hospital

Clinic

Other

IL-17 Targeting Biological Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global IL-17 Targeting Biological Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IL-17 Targeting Biological Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IL-17 Targeting Biological Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze IL-17 Targeting Biological Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Targeting Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Targeting Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Targeting Biological Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-17 Targeting Biological Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IL-17 Targeting Biological Drugs industry.

Chapter 3: Detailed analysis of IL-17 Targeting Biological Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IL-17 Targeting Biological Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IL-17 Targeting Biological Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IL-17 Targeting Biological Drugs Industry Trends Table 2. IL-17 Targeting Biological Drugs Industry Drivers Table 3. IL-17 Targeting Biological Drugs Industry Opportunities and Challenges Table 4. IL-17 Targeting Biological Drugs Industry Restraints Table 5. Global IL-17 Targeting Biological Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IL-17 Targeting Biological Drugs Revenue Share by Company (2021-2026) Table 7. Global IL-17 Targeting Biological Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global IL-17 Targeting Biological Drugs Sales Volume Share by Company (2021-2026) Table 9. Global IL-17 Targeting Biological Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IL-17 Targeting Biological Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global IL-17 Targeting Biological Drugs Key Company Manufacturing Base & Headquarters Table 12. Global IL-17 Targeting Biological Drugs Company, Product Type & Application Table 13. Global IL-17 Targeting Biological Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-17 Targeting Biological Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Global IL-17 Targeting Biological Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global IL-17 Targeting Biological Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global IL-17 Targeting Biological Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global IL-17 Targeting Biological Drugs Sales Volume Share by Type (2021-2026) Table 23. Global IL-17 Targeting Biological Drugs Sales Volume Share by Type (2027-2032) Table 24. Global IL-17 Targeting Biological Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global IL-17 Targeting Biological Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global IL-17 Targeting Biological Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global IL-17 Targeting Biological Drugs Sales Value Share by Type (2021-2026) Table 28. Global IL-17 Targeting Biological Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global IL-17 Targeting Biological Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global IL-17 Targeting Biological Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global IL-17 Targeting Biological Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global IL-17 Targeting Biological Drugs Sales Volume Share by Application (2021-2026) Table 36. Global IL-17 Targeting Biological Drugs Sales Volume Share by Application (2027-2032) Table 37. Global IL-17 Targeting Biological Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global IL-17 Targeting Biological Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global IL-17 Targeting Biological Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global IL-17 Targeting Biological Drugs Sales Value Share by Application (2021-2026) Table 41. Global IL-17 Targeting Biological Drugs Sales Value Share by Application (2027-2032) Table 42. Global IL-17 Targeting Biological Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global IL-17 Targeting Biological Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global IL-17 Targeting Biological Drugs Sales Market Share by Region (2021-2026) Table 45. Global IL-17 Targeting Biological Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global IL-17 Targeting Biological Drugs Sales Market Share by Region (2027-2032) Table 47. Global IL-17 Targeting Biological Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global IL-17 Targeting Biological Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global IL-17 Targeting Biological Drugs Sales Value Share by Region (2021-2026) Table 50. Global IL-17 Targeting Biological Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global IL-17 Targeting Biological Drugs Sales Value Share by Region (2027-2032) Table 52. Global IL-17 Targeting Biological Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global IL-17 Targeting Biological Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global IL-17 Targeting Biological Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global IL-17 Targeting Biological Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global IL-17 Targeting Biological Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global IL-17 Targeting Biological Drugs Sales Market Share by Country (2021-2026) Table 58. Global IL-17 Targeting Biological Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global IL-17 Targeting Biological Drugs Sales Market Share by Country (2027-2032) Table 60. Global IL-17 Targeting Biological Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global IL-17 Targeting Biological Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global IL-17 Targeting Biological Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global IL-17 Targeting Biological Drugs Sales Value Market Share by Country (2027-2032) Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. AstraZeneca IL-17 Targeting Biological Drugs Product Portfolio Table 68. AstraZeneca Recent Development Table 69. DICE Therapeutics Company Information Table 70. DICE Therapeutics Business Overview Table 71. DICE Therapeutics IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. DICE Therapeutics IL-17 Targeting Biological Drugs Product Portfolio Table 73. DICE Therapeutics Recent Development Table 74. Eli Lilly and Co. Company Information Table 75. Eli Lilly and Co. Business Overview Table 76. Eli Lilly and Co. IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Eli Lilly and Co. IL-17 Targeting Biological Drugs Product Portfolio Table 78. Eli Lilly and Co. Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Novartis IL-17 Targeting Biological Drugs Product Portfolio Table 83. Novartis Recent Development Table 84. UCB Company Information Table 85. UCB Business Overview Table 86. UCB IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. UCB IL-17 Targeting Biological Drugs Product Portfolio Table 88. UCB Recent Development Table 89. Jiangsu Hengrui Medicine Company Information Table 90. Jiangsu Hengrui Medicine Business Overview Table 91. Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Product Portfolio Table 93. Jiangsu Hengrui Medicine Recent Development Table 94. Akesobio Company Information Table 95. Akesobio Business Overview Table 96. Akesobio IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Akesobio IL-17 Targeting Biological Drugs Product Portfolio Table 98. Akesobio Recent Development Table 99. Chongqing Genrix Biopharmaceutical Company Information Table 100. Chongqing Genrix Biopharmaceutical Business Overview Table 101. Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Product Portfolio Table 103. Chongqing Genrix Biopharmaceutical Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. IL-17 Targeting Biological Drugs Distributors List Table 107. IL-17 Targeting Biological Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. IL-17 Targeting Biological Drugs Product Image Figure 2. Global IL-17 Targeting Biological Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global IL-17 Targeting Biological Drugs Sales (2021-2032) & (K Units) Figure 5. Global IL-17 Targeting Biological Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IL-17 Targeting Biological Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Global IL-17 Targeting Biological Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global IL-17 Targeting Biological Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global IL-17 Targeting Biological Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global IL-17 Targeting Biological Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global IL-17 Targeting Biological Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global IL-17 Targeting Biological Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global IL-17 Targeting Biological Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global IL-17 Targeting Biological Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global IL-17 Targeting Biological Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global IL-17 Targeting Biological Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global IL-17 Targeting Biological Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global IL-17 Targeting Biological Drugs Sales Value Share by Application (2021-2032) Figure 26. Global IL-17 Targeting Biological Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global IL-17 Targeting Biological Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global IL-17 Targeting Biological Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global IL-17 Targeting Biological Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America IL-17 Targeting Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe IL-17 Targeting Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific IL-17 Targeting Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America IL-17 Targeting Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa IL-17 Targeting Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa IL-17 Targeting Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. IL-17 Targeting Biological Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. IL-17 Targeting Biological Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • AstraZeneca
  • DICE Therapeutics
  • Eli Lilly and Co.
  • Novartis
  • UCB
  • Jiangsu Hengrui Medicine
  • Akesobio
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  4. 1.2.2 Global IL-17 Targeting Biological Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global IL-17 Targeting Biological Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IL-17 Targeting Biological Drugs Market Dynamics
  1. 2.1 IL-17 Targeting Biological Drugs Industry Trends
  2. 2.2 IL-17 Targeting Biological Drugs Industry Drivers
  3. 2.3 IL-17 Targeting Biological Drugs Industry Opportunities and Challenges
  4. 2.4 IL-17 Targeting Biological Drugs Industry Restraints
3 IL-17 Targeting Biological Drugs Market by Company
  1. 3.1 Global IL-17 Targeting Biological Drugs Company Revenue Ranking in 2025
  2. 3.2 Global IL-17 Targeting Biological Drugs Revenue by Company (2021-2026)
  3. 3.3 Global IL-17 Targeting Biological Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global IL-17 Targeting Biological Drugs Average Price by Company (2021-2026)
  5. 3.5 Global IL-17 Targeting Biological Drugs Company Ranking (2024-2026)
  6. 3.6 Global IL-17 Targeting Biological Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global IL-17 Targeting Biological Drugs Company Product Type and Application
  8. 3.8 Global IL-17 Targeting Biological Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IL-17 Targeting Biological Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IL-17 Targeting Biological Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IL-17 Targeting Biological Drugs Market by Type
  1. 4.1 IL-17 Targeting Biological Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global IL-17 Targeting Biological Drugs Sales Volume by Type
  5. 4.2.1 Global IL-17 Targeting Biological Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global IL-17 Targeting Biological Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global IL-17 Targeting Biological Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global IL-17 Targeting Biological Drugs Sales Value by Type
  9. 4.3.1 Global IL-17 Targeting Biological Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global IL-17 Targeting Biological Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global IL-17 Targeting Biological Drugs Sales Value Share by Type (2021-2032)
5 IL-17 Targeting Biological Drugs Market by Application
  1. 5.1 IL-17 Targeting Biological Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Targeting Biological Drugs Sales Volume by Application
  6. 5.2.1 Global IL-17 Targeting Biological Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Targeting Biological Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global IL-17 Targeting Biological Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global IL-17 Targeting Biological Drugs Sales Value by Application
  10. 5.3.1 Global IL-17 Targeting Biological Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-17 Targeting Biological Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global IL-17 Targeting Biological Drugs Sales Value Share by Application (2021-2032)
6 IL-17 Targeting Biological Drugs Regional Sales and Value Analysis
  1. 6.1 Global IL-17 Targeting Biological Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-17 Targeting Biological Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IL-17 Targeting Biological Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global IL-17 Targeting Biological Drugs Sales by Region (2027-2032)
  5. 6.3 Global IL-17 Targeting Biological Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IL-17 Targeting Biological Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global IL-17 Targeting Biological Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global IL-17 Targeting Biological Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global IL-17 Targeting Biological Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  12. 6.6.2 North America IL-17 Targeting Biological Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe IL-17 Targeting Biological Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IL-17 Targeting Biological Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  21. 6.9.2 South America IL-17 Targeting Biological Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IL-17 Targeting Biological Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IL-17 Targeting Biological Drugs Sales Value Share by Country, 2025 VS 2032
7 IL-17 Targeting Biological Drugs Country-level Sales and Value Analysis
  1. 7.1 Global IL-17 Targeting Biological Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IL-17 Targeting Biological Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IL-17 Targeting Biological Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global IL-17 Targeting Biological Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global IL-17 Targeting Biological Drugs Sales by Country (2027-2032)
  6. 7.4 Global IL-17 Targeting Biological Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global IL-17 Targeting Biological Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global IL-17 Targeting Biological Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IL-17 Targeting Biological Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IL-17 Targeting Biological Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IL-17 Targeting Biological Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca IL-17 Targeting Biological Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 DICE Therapeutics
  8. 8.2.1 DICE Therapeutics Company Information
  9. 8.2.2 DICE Therapeutics Business Overview
  10. 8.2.3 DICE Therapeutics IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 DICE Therapeutics IL-17 Targeting Biological Drugs Product Portfolio
  12. 8.2.5 DICE Therapeutics Recent Developments
  13. 8.3 Eli Lilly and Co.
  14. 8.3.1 Eli Lilly and Co. Company Information
  15. 8.3.2 Eli Lilly and Co. Business Overview
  16. 8.3.3 Eli Lilly and Co. IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Co. IL-17 Targeting Biological Drugs Product Portfolio
  18. 8.3.5 Eli Lilly and Co. Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis IL-17 Targeting Biological Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 UCB
  26. 8.5.1 UCB Company Information
  27. 8.5.2 UCB Business Overview
  28. 8.5.3 UCB IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 UCB IL-17 Targeting Biological Drugs Product Portfolio
  30. 8.5.5 UCB Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Akesobio
  38. 8.7.1 Akesobio Company Information
  39. 8.7.2 Akesobio Business Overview
  40. 8.7.3 Akesobio IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Akesobio IL-17 Targeting Biological Drugs Product Portfolio
  42. 8.7.5 Akesobio Recent Developments
  43. 8.8 Chongqing Genrix Biopharmaceutical
  44. 8.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 8.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 8.8.3 Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Product Portfolio
  48. 8.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-17 Targeting Biological Drugs Value Chain Analysis
  2. 9.1.1 IL-17 Targeting Biological Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-17 Targeting Biological Drugs Sales Mode & Process
  6. 9.2 IL-17 Targeting Biological Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-17 Targeting Biological Drugs Distributors
  9. 9.2.3 IL-17 Targeting Biological Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst